Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes, Steven M. Walker, Laura E. Taggart, et al.
JNCI Journal of the National Cancer Institute (2016) Vol. 109, Iss. 1, pp. djw199-djw199
Open Access | Times Cited: 412

Showing 1-25 of 412 citing articles:

PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord, Alan Ashworth
Science (2017) Vol. 355, Iss. 6330, pp. 1152-1158
Open Access | Times Cited: 2344
DNA sensing by the cGAS–STING pathway in health and disease
Mona Motwani, Scott Pesiridis, Katherine A. Fitzgerald
Nature Reviews Genetics (2019) Vol. 20, Iss. 11, pp. 657-674
Closed Access | Times Cited: 1109
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilié, Chad Tang, Gordon B. Mills, et al.
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 81-104
Open Access | Times Cited: 969
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
John Kwon, Samuel F. Bakhoum
Cancer Discovery (2019) Vol. 10, Iss. 1, pp. 26-39
Open Access | Times Cited: 873
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 91-113
Closed Access | Times Cited: 809
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen, B. Leticia Rodriguez, Limo Chen, et al.
Cancer Discovery (2019) Vol. 9, Iss. 5, pp. 646-661
Open Access | Times Cited: 719
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, et al.
Cancer Cell (2021) Vol. 39, Iss. 3, pp. 346-360.e7
Open Access | Times Cited: 688
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
Martin McLaughlin, Emmanuel C. Patin, Malin Pedersen, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 4, pp. 203-217
Closed Access | Times Cited: 631
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, et al.
Cancer Discovery (2017) Vol. 7, Iss. 7, pp. 675-693
Open Access | Times Cited: 582
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 548
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer
L.S. Ong, Wee Chyan Lee, Shijun Ma, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 31
Open Access | Times Cited: 544
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou, Olmo Sonzogni, Mateus de Oliveira Taveira, et al.
Cancer Discovery (2019) Vol. 9, Iss. 6, pp. 722-737
Open Access | Times Cited: 539
PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 528
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen, Wei Zhao, Zhenlin Ju, et al.
Cancer Research (2018) Vol. 79, Iss. 2, pp. 311-319
Open Access | Times Cited: 486
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding, Hye‐Jung Kim, Qiwei Wang, et al.
Cell Reports (2018) Vol. 25, Iss. 11, pp. 2972-2980.e5
Open Access | Times Cited: 467
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 17, pp. 1685-1694
Open Access | Times Cited: 461
Life and death of circulating cell-free DNA
Anatoli Kustanovich, Ruth Schwartz, Tamar Peretz, et al.
Cancer Biology & Therapy (2019) Vol. 20, Iss. 8, pp. 1057-1067
Open Access | Times Cited: 450
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy
Karsten Krug, Eric J. Jaehnig, Shankha Satpathy, et al.
Cell (2020) Vol. 183, Iss. 5, pp. 1436-1456.e31
Open Access | Times Cited: 404
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 364
Interferons α and β in cancer: therapeutic opportunities from new insights
Ernest C. Borden
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 3, pp. 219-234
Closed Access | Times Cited: 337
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 13, pp. 3759-3771
Open Access | Times Cited: 291
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Chun Gwon Park, Christina Hartl, Daniela Schmid, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 433
Open Access | Times Cited: 284
Dendritic cell subsets in cancer immunity and tumor antigen sensing
Annalisa Del Prete, Valentina Salvi, Alessandra Soriani, et al.
Cellular and Molecular Immunology (2023) Vol. 20, Iss. 5, pp. 432-447
Open Access | Times Cited: 280
PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 3, pp. 1211-1228
Open Access | Times Cited: 270
Ovarian Cancer Immunotherapy and Personalized Medicine
Susan Morand, Monika Devanaboyina, Hannah Staats, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6532-6532
Open Access | Times Cited: 253
Page 1 - Next Page

Scroll to top